NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.45 -0.05 (-0.32 %)
(As of 07/18/2018 12:42 PM ET)
Previous Close$15.45
Today's Range$15.45 - $15.45
52-Week Range$15.26 - $24.64
Volume100 shs
Average Volume81,226 shs
Market Capitalization$767.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kiniksa Pharmaceuticals logoKiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KNSA
CUSIPN/A
Phone781-439-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio2.70
Quick Ratio2.70

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees47
Outstanding Shares48,440,000
Market Cap$767.74

The Truth About Cryptocurrencies

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

What price target have analysts set for KNSA?

4 brokerages have issued 1-year target prices for Kiniksa Pharmaceuticals' stock. Their forecasts range from $29.00 to $33.00. On average, they anticipate Kiniksa Pharmaceuticals' stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Ratings for Kiniksa Pharmaceuticals.

What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Kiniksa Pharmaceuticals' key competitors?

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen Mahoney, Pres and Chief Operating Officer
  • Mr. Thomas W. Beetham, Chief Legal Officer
  • Dr. John F. Paolini, Chief Medical Officer
  • Mr. Rasmus Holm-Jørgensen, Sr. VP, Chief Strategy and Portfolio Officer.

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

When did the company's quiet period expire?

Kiniksa Pharmaceuticals' quiet period expired on Tuesday, July 3rd. Kiniksa Pharmaceuticals had issued 8,477,777 shares in its public offering on May 24th. The total size of the offering was $152,599,986 based on an initial share price of $18.00. During the company's quiet period, insiders and underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

News headlines about KNSA stock have been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kiniksa Pharmaceuticals earned a news sentiment score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 44.72 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BAKER BROS. ADVISORS LP (20.40%) and FLYNN JAMES E (8.32%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Institutional Ownership Trends for Kiniksa Pharmaceuticals.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $15.45.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $767.74 million. Kiniksa Pharmaceuticals employs 47 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]


MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  15
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.